Status:
TERMINATED
An Evaluation of the Long-term Safety of Magnesium Iron Hydroxycarbonate
Lead Sponsor:
Ineos Healthcare Limited
Conditions:
Chronic Kidney Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study it to look at the safety of fermagate over longer periods of ...
Detailed Description
High levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (PTH), bone disease, formation of calcium deposits in the body, and...
Eligibility Criteria
Inclusion
- Taken at least one dose of double-blind medication during study IH 001 and either completed study IH 001 or were withdrawn due to reasons other than an AE considered related to study treatment
- Male or female subjects on active haemodialysis, aged 18 years or over
- Willing to abstain from taking any phosphate binder or oral magnesium-, aluminium-, or iron-containing products and preparations, other than the study medication;
- Willing to avoid any intentional changes in diet such as fasting, dieting or overeating;
- Willing to maintain their usual type and dose of Vitamin D supplementation.
Exclusion
- Participation in any other clinical trial using an investigational product or device within the previous 4 months;
- A significant history of alcohol, drug or solvent abuse in the opinion of the investigator;
- Any disease or condition, physical or psychological, which in the opinion of the investigator would compromise the safety of the subject or increase the likelihood of the subject being withdrawn;
- Clinically significant laboratory findings (for this subject population) in the opinion of the investigator.
- Any malignancy with the exception of basal cell carcinoma;
- A history of a motility disorder of the intestines, including, but not limited to, gastroparesis, ileus, pseudo-obstruction, megacolon, or mechanical obstruction;
- A significant illness in the 4 weeks before screening;
- Taking medication for seizures;
- A history of haemochromatosis;
- A history of serum ferritin concentration of ≥ 1000 ng/mL (excluding transient, treatment-induced ferritin elevation);
- A history of dysphagia or swallowing disorders;
- Female subjects who are lactating or pregnant. Women of childbearing potential (pre-menopausal and not surgically sterilised) unless they abstain from sexual intercourse or are using a reliable contraceptive method, that is, barrier methods, hormones or intrauterine device;
- Current haemoglobin concentration of \< 10.00 g/dL;
- Allergy to the IMP or its constituents.
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00358722
Start Date
July 1 2006
End Date
June 1 2008
Last Update
August 10 2009
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
1614 West 42nd Street
Pine Bluff, Arkansas, United States, 71603
2
US Renal Care
Stuttgart, Arkansas, United States, 72160
3
Davita Dialysis Center
Charlotte, North Carolina, United States, 28208
4
Southeast Renal Associates
Charlotte, North Carolina, United States, 28208